Maternal transmission of Alzheimer’s disease: Prodromal metabolic phenotype and the search for genes

Human Genomics

Volumn 4, Issue 3, 2010, Pages 170-193

  Mosconi, Lisa ^a   Berti, Valentina ^b   Swerdlow, Russell H ^c   Pupi, Alberto ^b   Duara, Ranjan ^d   de Leon, Mony ^a,e  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORENCE   (Italy)

^c MS2012   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Alzheimer s disease; Early detection; Late onset; Maternal transmission; Positron emission tomography

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ALZHEIMER DISEASE; BRAIN MAPPING; GENETIC PREDISPOSITION; GENETICS; HUMAN; METABOLISM; MOTHER; ONSET AGE; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; REVIEW;

AGE OF ONSET; ALZHEIMER DISEASE; BRAIN MAPPING; FLUORODEOXYGLUCOSE F18; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOTHERS; PHENOTYPE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 85027951376     PISSN: 14739542     EISSN: 14797364     Source Type: Journal    
DOI: 10.1186/1479-7364-4-3-170     Document Type: Review

References (171)

1. Kukull, W.A., Higdon, R., Bowen, J.D., McCormick, W.C. et al. (2002), ’Dementia and Alzheimer disease incidence: A prospective cohort study’, Arch. Neurol. Vol. 59, pp. 1737–1746.
2. Hebert, L.E., Scherr, P.A., Bienias, J.L., Bennett, D.A. et al. (2004), ‘State-specific projections through 2025 of Alzheimer disease preva-lence’, Neurology Vol. 62, p. 1645.
3. Fratiglioni, L., Grut, M., Forsell, Y., Viitanen, M. et al. (1991), ‘Prevalence of Alzheimer’s disease and other dementias in an elderly urban population: Relationship with age sex, and education’, Neurology Vol. 41, pp. 1886–1892.
4. Brookmeyer, R., Gray, S. and Kawas, C. (1998), ‘Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset’, Am. J. Public Health Vol. 88, pp. 1337–1342.
5. McKhann, G., Drachman, D., Folstein, M. et al. (1984), ‘Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS–ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease’, Neurology Vol. 34, pp. 939–944.
6. Ritchie, K. and Lovestone, S. (2002), ‘The dementias’, Lancet Vol. 360, pp. 1759–1766.
7. Mosconi, L., Brys, M., Switalski, R., Mistur, R. et al. (2007), ‘Maternal family history of Alzheimer’s disease predisposes to reduced brain glucose metabolism’, Proc. Natl. Acad. Sci. USAVol. 104, pp. 19067–19072.
8. Small, G.W., Bookheimer, S.Y., Thompson, P.M. et al. (2008), ‘Current and future uses of neuroimaging for cognitively impaired patients’, Lancet Neurol. Vol. 7, pp. 161–172.
9. Scheltens, P., Fox, N., Barkhof, F. and De Carli, C. (2002), ‘Structural magnetic resonance imaging in the practical assessment of dementia: Beyond exclusion’, Lancet Neurol. Vol. 1, pp. 13–21.
10. Mosconi, L. (2005), ‘Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease’, Eur. J. Nucl. Med. Mol. Imaging Vol. 32, pp. 486–510.
11. Silverman, D.H.S., Gambhir, S.S., Huang, H.W., Schwimmer, J. et al. (2002), ‘Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: A comparison of predicted costs and benefits’, J. Nucl. Med. Vol. 43, pp. 253–266.
12. Herholz, K., Carter, S.F. and Jones, M. (2007), ‘Positron emission tom-ography imaging in dementia’, Br. J. Radiol. Vol. 2, pp. 160–167.
13. Mosconi, L., Pupi, A. and de Leon, M.J. (2009), ‘Brain glucose hypo-metabolism and oxidative stress in preclinical Alzheimer’s disease’, Ann. NY Acad. Sci. Vol. 1147, pp. 180–195.
14. Klunk, W.E., Engler, H., Nordberg, A., Yamming, W. et al. (2004), ‘Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B’, Ann. Neurol. Vol. 55, pp. 306–319.
15. Kemppainen, N., Aalto, S., Wilson, I., Nagren, K. et al. (2006), ‘Voxel –based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease’, Neurology Vol. 67, pp. 1575–1580.
16. Pike, K.E., Savage, G., Villemagne, V.L., Ng, S. et al. (2007), ‘Beta – amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer’s disease’, Brain Vol. 130, pp. 2837–2844.
17. Mintun, M.A.M., LaRossa, G.N., Sheline, Y.I.M., Dence, C.S.M. et al. (2006), ‘[11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease’, Neurology Vol. 67, pp. 446–452.
18. Fagan, A.M., Mintun, M.A., Mach, R.H., Lee, S. et al. (2006), ‘Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid’, Ann. Neurol. Vol. 59, pp. 512–519.
19. Tanzi, R.E. and Bertram, L. (2001), ‘New frontiers in Alzheimer’s disease genetics’, Neuron Vol. 32, pp. 181–184.
20. St George–Hyslop, P. (2000), ‘Molecular genetics of Alzheimer’s disease’, Biol. Psychiatry Vol. 47, pp. 183–199.
21. Mirra, S.S., Heyman, A., McKeel, D., Sumi, S.M. et al. (1991), ‘The consortium to establish a registry for Alzheimer’s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease’, Neurology Vol. 41, pp. 479–486.
22. Price, J.L. and Morris, J.C. (1999), ‘Tangles and plaques in nondemen-ted aging and “preclinical” Alzheimer’s disease’, Ann. Neurol. Vol. 45, pp. 358–368.
23. Selkoe, D.J. (1997), ‘Alzheimer’s disease: Genotypes, phenotype, and treatments’, Science Vol. 275, pp. 630–631.
24. Lue, L.F., Kuo, Y.M., Roher, A.E., Brachova, L. et al. (1999), ‘Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease’, Am. J. Pathol. Vol. 155, pp. 853–862.
25. Yankner, B.A., Davies, L.R., Fisher, S., Villa-Komaroff, L. et al. (1989), ‘Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer’s disease’, Science Vol. 245, pp. 417–420.
26. Yankner, B.A., Duffy, L. and Kirschner, D. (1990), ‘Neurotrophic and neurotoxic effects of amyloid beta protein: Reversal by tachykinin neuropeptides’, Science Vol. 250, pp. 279–282.
27. Geula, C., Wu, C.K., Saroff, D., Lorenzo, A. et al. (1998), ‘Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity’, Nat. Med. Vol. 4, pp. 827–831.
28. Behl, C., Davis, J., Lesley, R. and Schubert, D. (1994), ‘Hydrogen per-oxide mediates amyloid [beta]protein toxicity’, Cell Vol. 77, pp. 817–827.
29. Selkoe, D.J. (2001), ‘Clearing the brain’s amyloid cobwebs’, Neuron Vol. 32, pp. 177–180.
30. Kennedy, A.M., Frackowiak, R.S.J., Newman, S.K., Bloomfield, P.M. et al. (1995), ‘Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer’s disease’, Neurosci. Lett. Vol. 186, pp. 17–20.
31. Mosconi, L., Sorbi, S., de Leon, M.J., Nacmias, B. et al. (2006), ‘Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer’s disease’, J. Nucl. Med. Vol. 47, pp. 1778–1786.
32. Klunk, W.E., Price, J.C., Mathis, C.A., Tsopelas, N.D. et al. (2007), ‘Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees’, J. Neurosci. Vol. 27, pp. 6174–6184.
33. Koivunen, J., Verkkoniemi, S., Aalto, S., Paetau, A. et al. (2008), ‘PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer’s disease’, Brain Vol. 131, pp. 1845–1853.
34. Remes, A.M., Laru, L., Tuominen, H., Aalto, S. et al. (2008), ‘Carbon 11-labeled Pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication’, Arch. Neurol. Vol. 65, pp. 540–544.
35. Di Fede, G., Catania, M., Morbin, M., Rossi, G. et al. (2009), ‘A reces-sive mutation in the APP gene with dominant-negative effect on amy-loidogenesis’, Science Vol. 323, pp. 1473–1477.
36. Tomiyama, T., Nagata, T., Shimada, H., Teraoka, R. et al. (2008), ‘A new amyloid B variant favoring oligomerization in Alzheimer’s-type dementia’, Ann. Neurol. Vol. 63, pp. 377–387.
37. Gatz, M., Reynolds, C.A., Fratiglioni, L., Johansson, B. et al. (2006), ‘Role of genes and environments for explaining Alzheimer disease’, Arch. Gen. Psychiatry Vol. 63, pp. 168–174.
38. Gatz, M., Pedersen, N.L., Berg, S., Johansson, B. et al. (1997), ‘Heritability for Alzheimer’s disease: The study of dementia in Swedish twins’, J. Gerontol. A Biol. Sci. Med. Sci. Vol. 52, pp. 117–125.
39. Raiha, I., Kaprio, J., Koskenvuo, M., Johansson, B. et al. (1996), ‘Alzheimer’s disease in Finnish twins’, Lancet Vol. 347, pp. 573–578
40. Strittmatter, W.J., Saunders, A.M., Schmechel, D., Pericak-Vance, M. et al. (1993), ‘Apolipoprotein E: High-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease’, Proc. Natl. Acad. Sci. USAVol. 90, pp. 1977–1981.
41. Schmechel, D.E., Saunders, A.M., Strittmatter, W.J., Crain, B.J. et al. (1993), ‘Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease’, Proc. Natl. Acad. Sci. USAVol. 90, pp. 9649–9653.
42. Holtzman, D.M., Bales, K.R., Tenkova, T., Fagan, A.M. et al. (2000), ‘Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease’, Proc. Natl. Acad. Sci. USAVol. 97, pp. 2892–2897.
43. Holtzman, D.M. (2001), ‘Role of apoE/A interactions in the pathogen-esis of Alzheimer’s disease and cerebral amyloid angiopathy’, J. Mol. Neurosci. Vol. 17, pp. 147–155.
44. DeMattos, R.B. (2004), ‘Apolipoprotein E dose-dependent modulation of beta-amyloid deposition in a transgenic mouse model of Alzheimer’s disease’, J. Mol. Neurosci. Vol. 23, pp. 255–262.
45. Bennet, D.A., Schneider, J.A., Wilson, R.S., Bienias, J.L. et al. (2005), ‘Amyloid mediates the association of apolipoprotein E e4 allele to cognitive function in older people’, J. Neurol. Neurosurg. Psych. Vol. 76, pp. 1194–1199.
46. Laws, S.M., Hone, E., Gandy, S. and Martins, R.N. (2003), ‘Expanding the association between the APOE gene and the risk of Alzheimer’s disease: Possible roles for APOE promoter polymorphisms and alterations in APOE transcription’. J. Neurochem. Vol. 84, pp. 1215–1236.
47. Reiman, E.M., Uecker, A., Caselli, R.J., Lewis, S. et al. (1998), ‘Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer’s disease’, Ann. Neurol. Vol. 44, pp. 288–291.
48. Geroldi, C., Pihlajamaki, M., Laakso, M.P., DeCarli, C. et al. (1999), ‘APOE–epsilon4 is associated with less frontal and more medial tem-poral lobe atrophy in AD’, Neurology Vol. 53, pp. 1825–1832.
49. Small, G.W., Mazziotta, J.C., Collins, M.T., Baxter, L.R. et al. (1995), ‘Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease’, JAMA Vol. 273, pp. 942–947.
50. Small, G.W., Ercoli, L.M., Silverman, D.H.S., Huang, S.C. et al. (2000), ‘Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease’, Proc. Natl. Acad. Sci. USA Vol. 97, pp. 6037–6042.
51. Reiman, E.M., Caselli, R.J., Chen, K., Alexander, G.E. et al. (2001), ‘Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer’s disease’, Proc. Natl. Acad. Sci. USAVol. 98, pp. 3334–3339.
52. Reiman, E.M., Chen, K., Alexander, G.E., Caselli, R.J. et al. (2004), ‘Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia’, Proc. Natl. Acad. Sci. USA Vol. 101, pp. 284–289.
53. Rogaeva, E., Meng, Y., Lee, J.H., Gu, Y. et al. (2007), ‘The neuronal sortilin–related receptor SORL1 is genetically associated with Alzheimer disease’, Nat. Genet. Vol. 39, pp. 168–177.
54. Lee, J.H., Cheng, R., Schupf, N., Manly, J. et al. (2007), ‘The association between genetic variants in SORL1 and Alzheimer disease in an urban, multiethnic, community-based cohort’, Arch. Neurol. Vol. 64, pp. 501–506.
55. Lee, J.H., Shibata, N., Cheng, R. and Mayeux, R. (2008), ‘Possible association between SORL1 and Alzheimer disease?’, Dement. Geriatr. Cogn. Disord. Vol. 26, p. 482.
56. Meng, Y., Lee, J.H., Cheng, R. and Mayeux, R. (2007), ‘Association between SORL1 and Alzheimer disease in a genome-wide study’, Neuroreport Vol. 18, pp. 1761–1764.
57. Dodson, S.E., Gearing, M., Lippa, C.F., Montine, T.J. et al. (2006), ‘LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease’, J. Neuropathol. Exp. Neurol. Vol. 65, pp. 866–872.
58. Kolsch, H., Jessen, F., Wiltfang, J., Lewczuk, P. et al. (2008), ‘Influence of SORL1 gene variants: Association with CSF amyloid-beta products in probable Alzheimer’s disease’, Neurosci. Lett. Vol. 440, pp. 68–71.
59. Cuenco, K.T., Lunetta, K.L., Baldwin, C.T., McKee, A.C. et al. (2008), ‘Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease’, Arch. Neurol. Vol. 65, pp. 1640–1648.
60. Reiman, E.M., Webster, J.A., Myers, A.J., Hardy, J. et al. (2007), ‘GAB2 alleles modify Alzheimer’s risk in APOE e4 carriers’, Neuron Vol. 54, pp. 713–720.
61. Sleegers, K., Bettens, K., Brouwers, N., Engelborghs, S. et al. (2008), ‘Common variation in GRB-associated binding protein 2 (GAB2) and increased risk for Alzheimer dementia’, Hum. Mutat. Vol. 29, pp. 338–344.
62. Gu, H., Saito, K., Klaman, L.D., Fleming, T. et al. (2001), ‘Essential role for Gab2 in the allergic response’, Nature Vol. 412, pp. 186–190.
63. Haas, I.G., Frank, M., Veron, N. and Kemler, R. (2005), ‘Presenilin-dependent processing and nuclear function of gamma-protocadherins’. J. Biol. Chem. Vol. 280, pp. 9313–9319.
64. Carrasquillo, M.M., Zou, F., Pankratz, V.S., Wilcox, S.L. et al. (2009), ‘Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer’s disease’, Nat. Genet. Vol. 41, pp. 192–198.
65. Papassotiropoulos, A., Stephan, D.A., Huentelman, M.J., Hoerndli, F.J. et al. (2006), ‘Common KIBRA alleles are associated with human memory performance’, Science Vol. 314, pp. 475–478.
66. Almeida, O.P., Schwab, S.G., Lautenschlager, N.T., Morar, B. et al. (2008), ‘KIBRA genetic polymorphism influences episodic memory in later life, but does not increase the risk of mild cognitive impairment’, J. Cell. Mol. Med. Vol. 12, pp. 1672–1676.
67. Corneveaux, J.J., Liang, W.S., Reiman, E.M. et al. (2008), ‘Evidence for an association between KIBRA and late-onset Alzheimer’s disease’, Neurobiol. Aging doi:10.1016/jneurobiolaging2008.07. [Epub ahead of print]
68. Rodriguez –Rodriguez, E., Infanti, J., Llorca, J., Mateo, I. et al. (2009), ‘Age-dependent association of KIBRA genetic variation and Alzheimer’s disease risk’, Neurobiol. Aging Vol. 30, pp. 322–324.
69. Mayeux, R. and Hyslop, P.S. (2008), ‘Alzheimer’s disease: Advances in trafficking’, Lancet Neurol. Vol. 7, pp. 2–3.
70. Farrer, L.A., Cupples, L.A., Haines, J.L., Hyman, B. et al. (1997), ‘Effects of age, sex, and ethnicity on the association between apolipo-protein E genotype and Alzheimer disease’, JAMA Vol. 278, pp. 1349–1356.
71. Silverman, J.M., Raiford, K., Edland, S., Fillenbaum, G. et al. (1994), ‘The consortium to establish a registry for Alzheimer’s disease (CERAD). Part VI. Family history assessment: A multicenter study of first degree relatives of Alzheimer’s disease probands and nondemented spouse controls’, Neurology Vol. 44, pp. 1253–1259.
72. Cupples, L.A., Farrer, L.A., Sadovnik, A.D., Relkin, N. et al. (2004), ‘Estimating risk curves for first-degree relatives of patients with Alzheimer’s disease: The REVEAL study’, Genet. Med. Vol. 6, pp. 192–196.
73. Green, R.C., Cupples, L.A., Go, R., Benke, K.S. et al. (2002), ‘Risk of dementia among white and African American relatives of patients with Alzheimer disease’, JAMAVol. 287, pp. 329–336.
74. Silverman, J.M., Ciresi, G., Smith, C.J., Marin, D.B. et al. (2005), ‘Variability of familial risk of Alzheimer disease across the late life span’, Arch. Gen. Psychiat. Vol. 62, pp. 565–573.
75. Jayadev, S., Steinbart, E.J., Chi, Y.Y., Kukull, W.A. et al. (2008), ‘Conjugal Alzheimer disease’, Arch. Neurol. Vol. 65, pp. 373–378.
76. Bird, T.D., Nemens, E.J. and Kukull, W.A. (1993), ‘Conjugal Alzheimer’s disease: Is there an increased risk in offspring?’, Ann. Neurol. Vol. 34, pp. 396–399.
77. Duara, R., Lopez-Alberola, R.F., Barker, W.W., Loewenstein, D.A. et al. (1993), ‘A comparison of familial and sporadic Alzheimer’s disease’, Neurology Vol. 43, pp. 1377–1384.
78. Edland, S.D., Silverman, J.M., Peskind, E.R., Tsuang, D. et al. (1996), ‘Increased risk of dementia in mothers of Alzheimer’s disease cases: Evidence for maternal inheritance’, Neurology Vol. 47, pp. 254–256.
79. Ehrenkrantz, D., Silverman, J.M., Smith, C.J., Tsuang, D. et al. (1999), ‘Genetic epidemiological study of maternal and paternal transmission of Alzheimer’s disease’. Am. J. Med. Genet. Vol. 88, pp. 378–382.
80. Gomez –Tortosa, E., Barquero, M.S., Baron, M., Saint, H.J. et al. (2007), ‘Variability of age at onset in siblings with familial Alzheimer disease’. Arch. Neurol. Vol. 64, pp. 1743–1748.
81. Heyman, A., Wilkinson, W.E., Hurwitz, B.J., Schmechel, D. et al. (1983), ‘Alzheimer’s disease: Genetic aspects and associated clinical dis-orders’, Ann. Neurol. Vol. 14, pp. 507–515.
82. Seshadri, S., Wolf, P.A., Beiser, A., Au, R. et al. (1996), ‘Lifetime risk of dementia and Alzheimer’s disease: Estimates from the Framingham study’, Neurology Vol. 46, pp. 411–412.
83. Duara, R., Barker, W.W., Lopez –Alberola, R., Loewenstein, D.A. et al. (1996), ‘Alzheimer’s disease: Interaction of apolipoprotein E genotype, family history of dementia, gender, education, ethnicity, and age of onset’, Neurology Vol. 46, pp. 1575–1579.
84. Mosconi, L., Mistur, R., Glodzik, L., Brys, M. et al. (2009), ‘Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer’s’, Neurology Vol. 72, pp. 513–520.
85. de Leon, M.J., Convit, A., Wolf, O.T., Tarshish, C.Y. et al. (2001), ‘Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET)’, Proc. Natl. Acad. Sci. USAVol. 98, pp. 10966–10971.
86. Mosconi, L., De Santi, S., Li, J., Tsui, W.H. et al. (2008), ‘Hippocampal hypometabolism predicts cognitive decline from normal aging’, Neurobiol. Aging Vol. 29, pp. 676–692.
87. Constancia, M., Kelsey, G. and Relk, W. (2004), ‘Resourceful imprint-ing’, Nature Vol. 432, pp. 53–57.
88. Gold, J.D. and Pedersen, R.A. (1994), ‘Mechanisms of genomic imprinting in mammals’, Curr. Top. Dev. Biol. Vol. 29, pp. 227–280.
89. Moore, T. and Haig, D. (1991), ‘Genomic imprinting in mammalian development: A parental tug-of-war’, Trends Genet. Vol. 7, pp. 45–49.
90. Payao, S.L., Smith, M.D. and Bertolucci, P.H. (1998), ‘Differential chromosome sensitivity to 5-azacytidine in Alzheimer’s disease’, Gerontology Vol. 44, pp. 267–271.
91. Bassett, S.S., Avramopoulos, D. and Fallin, D. (2002), ‘Evidence for parent of origin effect in late-onset Alzheimer disease’, Am. J. Med. Genet. Vol. 114, pp. 679–686.
92. Csaba, G. (2008), ‘Hormonal imprinting: Phylogeny, ontogeny, diseases and possible role in present-day human evolution’, Cell Biochem. Funct. Vol. 26, pp. 1–10.
93. Wilkinson, L.S., Davies, W. and Isles, A.R. (2007), ‘Genomic imprinting effects on brain development and function’, Nat. Rev. Neurosci. Vol. 8, pp. 832–843.
94. Davies, W., Isles, A., Smith, R., Karunadasa, D. et al. (2005), ‘Xlr3b is a new imprinted candidate for X-linked parent-of-origin effects on cognitive function in mice’, Nat. Genet. Vol. 37, pp. 625–629.
95. Lin, M.T. and Beal, M.F. (2006), ‘Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases’, Nature Vol. 443, pp. 787–795.
96. Schapira, A.H. (2006), ‘Mitochondrial disease’, Lancet Vol. 368, pp. 70–82.
97. Smith, M.A., Sayre, L.M., Monnier, V.M. and Perry, G. (1995), ‘Radical AGEing in Alzheimer’s disease’, Trends Neurosci. Vol. 18, pp. 172–176.
98. Mecocci, P., MacGarvey, U. and Beal, M.F. (1994), ‘Oxidative damage to mitochondrial DNA is increased in Alzheimer’s disease’, Ann. Neurol. Vol. 36, pp. 747–750.
99. Subbarao, K.V., Richardson, J.S. and Ang, L.C. (1990), ‘Autopsy samples of Alzheimer’s cortex show increased peroxidation in vitro’. J. Neurochem. Vol. 55, pp. 342–345.
100. Swerdlow, R.H. (2007), ‘Treating neuro degeneration by modifying mitochondria: Potential solutions to a “complex” problem’, Antiox. Redox Signal. Vol. 9, pp. 1591–1604.
101. Mutisya, E.M., Bowling, A.C. and Beal, M.F. (1994), ‘Cortical cyto-chrome oxidase activity is reduced in Alzheimer’s disease’, J.Neurochem. Vol. 63, pp. 2179–2184.
102. Hirai, K., Aliev, G., Nunomura, A., Fujioka, H. et al. (2001), ‘Mitochondrial abnormalities in Alzheimer’s disease’, J. Neurosci. Vol. 21, pp. 3017–3023.
103. Valla, J., Berndt, J.D. and Gonzales-Lima, F. (2001), ‘Energy hypometa-bolism in posterior cingulate cortex of Alzheimer’s patients: Superficial laminar cytochrome oxidase associated with disease duration’, J. Neurosci. Vol. 21, pp. 4923–4930.
104. Simonian, N.A. and Hyman, B.T. (1994), ‘Functional alterations in Alzheimer’s disease: Selective loss of mitochondrial-encoded cyto-chrome oxidase mRNA in the hippocampal formation’, J. Neuropathol. Exp. Neurol. Vol. 53, pp. 508–512.
105. Wong-Riley, M.T.T. (1989), ‘Cytochrome oxidase: An endogenous metabolic marker for neuronal activity’, Trends Neurosci. Vol. 12, pp. 94–101.
106. Hevner, R.F. and Wong-Riley, M.T. (1991), ‘Neuronal expression of nuclear and mitochondrial genes for cytochrome oxidase (CO) subunits analyzed by in situ hybridization: Comparison with CO activity and protein’, J. Neurosci. Vol. 11, pp. 1942–1958.
107. Parker, W.D., Jr, Filley, C.M. and Parks, J.K. (1990), ‘Cytochrome oxidase deficiency in Alzheimer’s disease’, Neurology Vol. 40, pp. 1302–1303.
108. Parker, W.D., Jr, Mahr, N.J., Filley, C.M., Parks, J.K. et al. (1994), ‘Reduced platelet cytochrome c oxidase activity in Alzheimer’s disease’, Neurology Vol. 44, pp. 1086–1090.
109. Chandrasekaran, K., Hatanpää, K., Rapoport, S.I. and Brady, D.R. (1997), ‘Decreased expression of nuclear and mitochondrial DNA-encoded genes of oxidative phosphorylation in association neocortex in Alzheimer disease’, Brain Res. Mol. Brain Res. Vol. 44, pp. 99–104.
110. Bosetti, F., Brizzi, F., Barogi, S., Mancuso, M. et al. (2002), ‘Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer’s disease’, Neurobiol. Aging Vol. 23, pp. 371–376.
111. Cardoso, S.M., Proenca, M.T., Santos, S. and de Oliveira, C.R. (2004), ‘Cytochrome c oxidase is decreased in Alzheimer’s disease platelets’, Neurobiol. Aging Vol. 25, pp. 105–110.
112. Valla, J., Schneider, L., Niedzielko, T., Coon, K.D. et al. (2006), ‘Impaired platelet mitochondrial activity in Alzheimer’s disease and mild cognitive impairment’, Mitochondrion Vol. 6, pp. 323–330.
113. Curti, D., Rognoni, F., Gasparini, L., Cattaneo, A. et al. (1997), ‘Oxidative metabolism in cultured fibroblasts derived from sporadic Alzheimer’s disease (AD) patients’, Neurosci. Lett. Vol. 236, pp. 13–16.
114. Kish, S.J., Bergeron, C., Rajput, A.H., Dozic, S. et al. (1992), ‘Brain cytochrome oxidase in Alzheimer’s disease’, J. Neurochem. Vol. 59, pp. 776–779.
115. Lucas, J.J. and Kates, J.R. (1976), ‘The construction of viable nuclear-cytoplasmic hybrid cells by nuclear transplantation’, Cell Vol. 7, pp. 397–405.
116. Swerdlow, R.H. and Khan, S.M. (2004), ‘A “mitochondrial cascade hypothesis” for sporadic Alzheimer’s disease’, Med. Hypotheses Vol. 63, pp. 8–20.
117. Swerdlow, R.H., Parks, J.K., Cassarino, D.S., Maguire, D.J. et al. (1997), ‘Cybrids in Alzheimer’s disease: A cellular model of the disease?’, Neurology Vol. 49, pp. 918–925.
118. Khan, S.M., Cassarino, D.S., Abramova, N.N., Keeney, P.M. et al. (2000), ‘Alzheimer’s disease cybrids replicate beta-amyloid abnormalities through cell death pathways’, Ann. Neurol. Vol. 48, pp. 148–155.
119. Trimmer, P.A., Swerdlow, R.H., Parks, J.K., Keeney, P.M. et al. (2000), ‘Abnormal mitochondrial morphology in sporadic Parkinson’s and Alzheimer’s disease cybrid cell lines’, Exp. Neurol. Vol. 162, pp. 37–50.
120. Cardoso, S.M., Santana, I., Swerdlow, R.H. and Oliveira, C.R. (2004), ‘Mitochondria dysfunction of Alzheimer’s disease cybrids enhances Abeta toxicity’, J. Neurochem. Vol. 89, pp. 1417–1426.
121. Coskun, P.E., Beal, M.F. and Wallace, D.C. (2004), ‘Alzheimer’s brains harbor somatic mtDNA controlregion mutations that suppress mito-chondrial transcription and replication’, Proc. Natl. Acad. Sci. USA Vol. 101, pp. 10726–10731.
122. Chinnery, P.F., Taylor, G.A., Howell, N., Brown, D.T. et al. (2001), ‘Point mutations of the mtDNA control region in normal and neurode-generative human brains’, Am. J. Hum. Genet. Vol. 68, pp. 529–532.
123. Corral-Debrinski, M., Horton, T., Lott, M.T., Shoffner, J.M. et al. (1994), ‘Marked changes in mitochondrial DNA deletion levels in Alzheimer brains’, Genomics Vol. 23, pp. 471–476.
124. Egensperger, R., Kosel, S., Schnopp, N.M., Mehraein, P. et al. (1997). ‘Association of the mitochondrial tRNA(A4336G) mutation with Alzheimer’s and Parkinson’s diseases’, Neuropathol. Appl. Neurobiol. Vol. 23, pp. 315–321.
125. Shoffner, J.M., Brown, M.D., Torroni, A., Lott, M.T. et al. (1993), ‘Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients’, Genomics Vol. 17, pp. 171–184.
126. Wragg, M.A., Talbot, C.J., Morris, J.C., Lendon, C.L. et al. (1995), ‘No association found between Alzheimer’s disease and a mitochondrial tRNA glutamine gene variant’, Neurosci. Lett. Vol. 201, pp. 107–110.
127. Carrieri, G., Bonafe, M., De Luca, M., Rose, G. et al. (2001), ‘Mitochondrial DNA haplogroups and APOE4 allele are non-independent variables in sporadic Alzheimer’s disease’, Hum. Genet. Vol. 108, pp. 194–198.
128. van der Walt, J.M., Dementieva, Y.A., Martin, E.R., Scott, W.K. et al. (2004), ‘Analysis of European mitochondrial haplogroups with Alzheimer disease risk’, Neurosci. Lett. Vol. 365, pp. 28–32.
129. Chagnon, P., Gee, M., Filion, M., Robitaille, Y. et al. (1999), ‘Phylogenetic analysis of the mitochondrial genome indicates significant differences between patients with Alzheimer disease and controls in a French-Canadian founder population’, Am. J. Med.Genet. Vol. 85, pp. 20–30.
130. Brouwer, J.R., Willemsen, R. and Oostra, B.A. (2009), ‘Microsatellite repeat instability and neurological disease’, Bioessays Vol. 31, pp. 71–83.
131. Kehoe, J.P., Krawczak, M., Harper, P.S., Owen, M.J. et al. (1999), ‘Age of onset in Huntington disease: Sex specific influence of apolipoprotein E genotype and normal CAG repeat length’, J. Med. Genet. Vol. 36, pp. 108–111.
132. Mandel, J.L. and Biancalana, V. (2004), ‘Fragile X mental retardation syndrome: From pathogenesis to diagnostic issue’, Growth Horm. IGF Res. Vol. 14 (Suppl. 1), pp. 158–165.
133. La Pean, A., Jeffries, N., Grow, C., Ravina, B. et al. (2008), ‘Predictors of progression in patients with Friedreich ataxia’, Mov. Disord. Vol. 23, pp. 2026–2032.
134. Botta, A., Rinaldi, F., Catalli, C., Vergani, L. et al. (2009), ‘The CTG repeat expansion size correlates with the splicing defects observed in muscles from myotonic dystrophy type 1 patients’, J.Med. Genet. Vol. 45, pp. 639–646.
135. Ashworth, A., Lloyd, S., Brown, J., Gydesen, S. et al. (1999), ‘Molecular genetic characterisation of frontotemporal dementia on chromosome 3’, Dement. Geriatr. Cogn. Disord. Vol. 10, pp. 93–101.
136. Mackenzie, I.R., Butland, S.L., Devon, R.S., Dwosh, E. et al. (2006), ‘Familial frontotemporal dementia with neuronal intranuclear inclusions is not a polyglutamine expansion disease’, BMC Neurol. Vol. 6, pp. 32–38.
137. Samii, A., Nutt, J.G. and Ransom, B.R. (2004), ‘Parkinson’s disease’, Lancet Vol. 363, pp. 1783–1793.
138. Wider, C. and Wszolek, Z.K. (2009), ‘Movement disorders: Insights into mechanisms and hopes for treatment’, Lancet Neurol. Vol. 8, pp. 8 – 10.
139. Banerjee, R., Starkov, A.A., Beal, M.F. and Thomas, B. (2008), ‘Mitochondrial dysfunction in the limelight of Parkinson’s disease pathogenesis’, Biochim. Biophys. Acta Vol. 1792, pp. 651–663.
140. Swerdlow, R.H., Parker, W.D., Currie, L.J., Bennett, J.P. et al. (2001), ‘Gender ratio differences between Parkinson’s disease patients and their affected relatives’, Parkinsonism Relat. Disord. Vol. 7, pp. 129–133.
141. Wooten, G.F., Currie, L.J., Bennet, J.P., Harrison, M.B. et al. (1997), ‘Maternal inheritance in Parkinson’s disease’, Ann. Neurol. Vol. 41, pp. 265–268.
142. van der Walt, J.M., Nicodemus, K.K., Martin, E.R., Scott, W.K. et al. (2003), ‘Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease’, Am. J. Hum. Genet. Vol. 72, pp. 804–811.
143. Pyle, A., Foltynie, T., Tiangyou, W., Lambert, C. et al. (2005), ‘Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD’, Ann. Neurol. Vol. 57, pp. 564–567.
144. Autere, J., Moilanen, J.S., Finnila, S., Soininen, H. et al. (2004), ‘Mitochondrial DNA polymorphisms as risk factors for Parkinson’s disease and Parkinson’s disease dementia’, Hum. Genet. Vol. 115, pp. 29–35.
145. Kirchner, S.C., Hallagan, S.E., Farin, F.M., Dilley, J. et al. (2000), ‘Mitochondrial ND1 sequence analysis and association of the T4216C mutation with Parkinson’s disease’, Neurotoxicology Vol. 21, pp. 441–445.
146. Huerta, C., Castro, M.G., Coto, E., Blazquez, M. et al. (2005), ‘Mitochondrial DNA polymorphisms and risk of Parkinson’s disease in Spanish population’, J. Neurol. Sci. Vol. 236, pp. 49–54.
147. Tan, E.K., Khajavi, M., Thornby, J.I., Nagamitsu, S. et al. (2000), ‘Variability and validity of polymorphism association studies in Parkinson’s disease’, Neurology Vol. 55, pp. 533–538.
148. Langston, J.W., Ballard, P.A., Tetrud, J.W. and Irwin, I. (1983), ‘Chronic parkinsonism in humans due to a product of meperidine-analog syn-thesis’, Science Vol. 219, pp. 979–980.
149. Betarbet, R., Sherer, T.B., MacKenzie, G., Garcia-Osuna, M. et al. (2000), ‘Chronic systemic pesticide exposure reproduces features of Parkinson’s disease’, Nat. Neurosci. Vol. 3, pp. 1301–1306.
150. Schapira, A.H.V., Cooper, J.M., Dexter, D., Jenner, P. et al. (1989), ‘Mitochondrial complex I deficiency in Parkinson’s disease’, Lancet Vol. 1, p. 1269.
151. Bindoff, L.A., Birch-Machin, M., Cartlidge, N.E.F., Parker, W.D.J. et al. (1989), ‘Mitochondrial function in Parkinson’s disease’, Lancet Vol. 2, p. 49.
152. Parker, W.D., Jr, Boyson, S.J. and Parks, J.K. (1989), ‘Electron transport chain abnormalities in idiopathic Parkinson’s disease’, Ann. Neurol. Vol. 26, pp. 719–723.
153. Schapira, A.H. (2007), ‘Mitochondrial dysfunction in Parkinson’s disease’, Cell Death Differ. Vol. 14, pp. 1261–1266.
154. Swerdlow, R.H., Parks, J.K., Miller, S.W., Tuttle, J.B. et al. (1996), ‘Origin and functional consequences of the complex I defect in Parkinson’s disease’, Ann. Neurol. Vol. 40, pp. 663–671.
155. Swerdlow, R.H. (2007), ‘Mitochondria in cybrids containing mtDNA from persons with mitochondriopathies’, J. Neurosci. Res. Vol. 85, pp. 3416–3428.
156. Swerdlow, R.H., Parks, J.K., Davis, J.N., Cassarino, D.S. et al. (1998), ‘Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson’s disease family’, Ann. Neurol. Vol. 44, pp. 873–881.
157. Maceluch, J.A. and Niedziela, M.(2007), ‘The clinical diagnosis and molecular genetics of Kearns –Sayre syndrome: A complex mitochondrial encephalomyopathy’, Pediatr. Endocrinol. Rev. Vol. 4, pp. 117–137.
158. Thambisetty, M. and Newman, N.J. (2004), ‘Diagnosis and manage-ment of MELAS’, Expert Rev. Mol. Diagn. Vol. 4, pp. 631–644.
159. DiMauro, S., Hirano, M., Kaufmann, P., Tanji, K. et al. (2002), ‘Clinical features and genetics of myoclonic epilepsy with ragged red fibers’, Adv. Neurol. Vol. 89, pp. 217–229.
160. Holt, I.J., Harding, A.E., Petty, R.K.H. and Morgan-Hughes, J.A. (1990), ‘A new mitochondrial disease associated with mitochon-drial DNA heteroplasmy’, Am. J. Hum. Genet. Vol. 46, pp. 428–433.
161. Yen, M.Y., Wang, A.G. and Wei, Y.H. (2006), ‘Leber’s hereditary optic neuropathy: A multifactorial disease’, Prog. Retin. Eye Res. Vol. 25, pp. 381–396.
162. Silvestri, G., Servidei, S., Rana, M., Ricci, E. et al. (1996), ‘A novel mitochondrial DNA point mutation in the tRNAIle gene is associated with progressive external ophthalmoplegia’, Biochem. Biophys. Res. Comm. Vol. 220, pp. 623–627.
163. Hosszufalusi, N., Karcagi, V., Horvath, R., Palik, E. et al. (2009), ‘A detailed investigation of maternally inherited diabetes and deafness (MIDD) including clinical characteristics, C-peptide secretion, HLA-DR and-DQ status and autoantibody pattern’, Diabetes Metab. Res. Rev. Vol. 25, pp. 127–135.
164. Pal, D.K., Durner, M., Klotz, I., Dicker, E. et al. (2006), ‘Complex inheritance and parent-of-origin effect in juvenile myoclonic epilepsy’, Brain Dev. Vol. 28, pp. 92–98.
165. Eapen, V., O’Neill, J., Gurling, H.M. and Robertson, M.M. (1997), ‘Sex of parent transmission effect in Tourette’s syndrome: Evidence for earlier age at onset in maternally transmitted cases suggests a genomic imprinting effect’, Neurology Vol. 48, pp. 801–802.
166. Horsthemke, B. and Wagstaff, J. (2008), ‘Mechanisms of imprinting of the Prader –Willi/Angelman region’, Am. J. Med. Genet. Vol. 146, pp. 2041–2052.
167. Cook, E.H., Jr, Lindgren, V., Leventhal, B.L., Courchesne, R. et al. (1997), ‘Autism or atypical autism in maternally but not paternally derived proximal 15q duplication’, Am. J. Hum.Genet. Vol. 60, pp. 928–934.
168. Brown, M.D., Starikovskaya, E., Derbeneva, O., Hosseini, S. et al. (2002), ‘The role of mtDNA background in disease expression: A new primary LHON mutation associated with Western Eurasian hap-logroup’, J. Hum. Genet. Vol. 110, pp. 130–138.
169. Selkoe, D.J. (2001), ‘Presenilin, Notch, and the genesis and treatment of Alzheimer’s disease’, Proc. Natl. Acad. Sci. USA Vol. 98, pp. 11039–11041.
170. Bothwell, M. and Giniger, E. (2000), ‘Alzheimer’s disease: Neurodevelopment converges with neurodegeneration’, Cell Vol. 102, pp. 271–273.
171. Nikolaev, A., McLaughlin, T., O’Leary, D.D. and Tessier –Lavigne, M. (2009), ‘APP binds DR6 to trigger axon pruning and neuron death via distinct caspases’, Nature Vol. 457, pp. 981–989.